ArticleSports medicine and health science2026
An exerkine-based prognostic index reveals immune heterogeneity and predicts outcomes across 33 cancers.
Article in Sports medicine and health science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Exercise exerts tumor-suppressive effects across multiple malignancies, partly through exerkines-exercise-induced secreted factors with immunomodulatory and metabolic functions. However, the prognostic relevance of exerkines across cancer types remains unclear, and the molecular determinants of exercise responsiveness are poorly defined. Methods: We systematically profiled 183 curated exerkine-related genes across 33 cancer types from The Cancer Genome Atlas (TCGA) using non-negative matrix factorization (NMF) to define molecular subtypes. Prognostic significance was evaluated via Kaplan-Meier analysis. For five cancers with consistent survival divergence (LGG, KIRC, LUAD, PAAD, ACC), we developed an Exerkine Prognostic Index (EPI) using LASSO Cox regression and validated its predictive performance through time-dependent ROC analysis. Immune cell infiltration (CIBERSORT), stromal/immune scores (ESTIMATE), and immune checkpoint expression were assessed to characterize immune landscape differences between EPI subgroups. Results: Exerkine-based NMF clustering identified prognostically distinct subtypes in 25 cancers. The EPI robustly stratified patients into high- and low-risk groups with significant differences in overall survival ( Discussion: Our findings reveal that exerkine expression patterns capture biologically and clinically relevant heterogeneity across cancers. The EPI provides a robust molecular tool to stratify patients by prognosis and immune contexture, offering insights into differential exercise responsiveness. Conclusions: Exerkines represent promising biomarkers for risk stratification and precision-guided exercise interventions in oncology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.